Business

President Trump Unveils Discounted Drugs Website

Published

1 month ago

6 February 2026

TrumpRx Launches: President Trump Unveils Discounted Drugs Website

President Donald Trump launched TrumpRx.gov Thursday, a new website promising “the world’s lowest prices” on dozens of popular prescription medications through direct discounts from major pharmaceutical companies. The platform arrives as a centerpiece of the administration’s aggressive push to slash drug costs for cash-paying Americans, bypassing insurance complexities and middlemen.

Speaking at a White House event flanked by Health and Human Services Secretary Robert F. Kennedy Jr., Centers for Medicare and Medicaid Services Administrator Dr. Mehmet Oz and Pfizer CEO Dr. Albert Bourla, Trump called TrumpRx “the most impactful price reset in our nation’s history.” The site debuted with savings on more than 40 drugs from five companies — AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer — with 11 more manufacturers joining soon.

Users visit TrumpRx.gov, search for their medication, print a digital coupon and redeem it at participating pharmacies for cash prices far below list costs. The White House touted examples like weight-loss drugs Ozempic and Wegovy dropping dramatically, fertility treatments and menopause relief like Duavee at 85% off, alongside autoimmune and overactive bladder medications.

How TrumpRx works: Cash discounts, no insurance required

TrumpRx targets the “cash-pay” market — patients without insurance coverage, those hitting deductibles or facing high copays. Visitors enter their medication, location and pharmacy preference to unlock coupon codes redeemable nationwide. GoodRx powers the backend pricing integration, streamlining access without manufacturer websites or eligibility forms.

Key disclaimers: Discounts apply only to cash payments, not insurance deductibles or covered benefits. The site emphasizes “self-pay patients” and excludes government programs initially, though Medicaid integration looms. Trump highlighted “Most Favored Nation” pricing deals exempting participating companies from U.S. tariffs, pressuring Big Pharma into voluntary cuts.

Initial offerings span chronic conditions: diabetes (Ozempic), obesity (Wegovy, Zepbound), autoimmune (Xeljanz), menopause (Duavee), eczema (Eucrisa) and more. A FAQ promises “many more drugs coming soon,” signaling expansion.

White House hails ‘Big Pharma-gouging’ endgame

Trump framed the launch as populist warfare against pharmaceutical pricing. “Thanks to President Trump, the days of Big Pharma-gouging are over,” the website declares. Administration officials cited U.S. patients paying 2-4 times more than Canadians or Europeans for identical drugs, blaming PBMs, rebates and lack of price competition.

RFK Jr. positioned TrumpRx within broader reforms: “This is Phase One. Direct-to-consumer transparency forces real competition.” Dr. Oz demoed the site live, pulling up Ozempic at $346 monthly versus $1,086 list — a 68% cut. Pfizer’s Bourla committed 30+ drugs immediately, calling it “a win for patients and innovation.”

The event echoed Trump’s first-term “Most Favored Nation” executive order, revived after court blocks. Participating firms gain tariff exemptions; non-joiners face import scrutiny. Critics call it coercive; supporters hail market disruption.

Drug-by-drug savings spotlight

TrumpRx spotlights blockbuster discounts:

Drug	Use	List Price (Monthly)	TrumpRx Price	Savings
Ozempic	Diabetes/Weight Loss	$1,086	$346	68%
Wegovy	Obesity	$1,349	$399	70%
Duavee	Menopause	$500+	$75	85%
Xeljanz	Autoimmune	$5,800	$1,200	79%
Eucrisa	Eczema	$700	$162	77%

Fertility drugs drew praise: IVF medications, often $10,000+ per cycle, slash to accessible levels. “This is a big deal for families,” noted one analyst.

Pharma partners and expansion roadmap

Launch partners pledged aggressively:

Pfizer: 30+ drugs, including menopause, autoimmune, bladder treatments.
Novo Nordisk: GLP-1 leaders Ozempic/Wegovy at fraction of list.
Eli Lilly: Zepbound, Orforglipron (pending FDA) at $346 monthly.
AstraZeneca, EMD Serono: Oncology, fertility additions imminent.

Eleven more firms — undisclosed — integrate within months. GoodRx’s role ensures pharmacy ubiquity; Walgreens, CVS, independents participate.

Critics question scope, sustainability

Skeptics abound. Dr. Christina Madison called it “GoodRx-like” but centralized: “Patient assistance repackaged — helpful, not revolutionary.” AARP warned discounts skip insured patients, leaving 150 million unaffected. Pharma lobby PhRMA stressed R&D needs: “Voluntary cuts can’t replace innovation incentives.”

Democrats decried cash-only limits: “Helps uninsured, ignores working families with crappy insurance,” tweeted Sen. Elizabeth Warren. GoodRx affirmed partnership: “We host self-pay prices, integrate seamlessly.”

Legal watchers eye MFN revival: Biden-era courts struck similar rules; Trump 2.0 tests fresh ground. Early traffic crashed TrumpRx.gov temporarily, signaling demand.

Patient stories fuel populist pitch

White House spotlit real users:

Sarah T., Ohio: Ozempic from $900 to $350 monthly — “Life-changing.”
Mike R., Texas: IVF drugs halved — “Dreams affordable now.”
Linda P., Florida: Duavee at $75 — “Menopause relief without bankruptcy.”

Trump touted 300 million potential beneficiaries: “Every American deserves medicine at fair prices.” RFK Jr. vowed Phase 2: insulin caps, PBM bans.

Timing ties to midterms, health care wars

Launch precedes 2026 midterms, where drug prices rank top voter concerns (72% per KFF). Gallup pegs affordability above inflation. Trump positions TrumpRx as 2024 promise kept: “I said I’d fix it — watch me deliver.” Polling shows 65% approval for direct discounts.

Globally, Canada/India parallel import threats loom if Pharma balks. EU praised transparency; WHO urged universality.

Tech behind TrumpRx: User-friendly disruption

Built on GoodRx infrastructure, TrumpRx offers geo-targeted pharmacy matching, mobile coupons, price comparisons. Spanish/English bilingual; ADA compliant. CMS integration teases Medicare expansion.

Beta testing yielded 92% redemption success; average savings $400 monthly per user. Site traffic hit 1M+ Thursday night.

Big Pharma’s reluctant embrace

Pfizer led buy-in: “Patients win, we innovate,” Bourla stated. Novo Nordisk followed, slashing GLP-1s amid Wegovy shortages. Eli Lilly timed with Zepbound; AstraZeneca eyes oncology next.

Non-participants risk tariffs, public backlash. Merck, J&J mum; analysts predict trickle joining by March.

What comes next for American drug prices

Phase 2 teases insulin at $35, EpiPens slashed, PBM rebate bans. Trump eyes Canada pharmacy flights if Pharma resists. RFK Jr. champions transparency laws mirroring Europe’s HTA systems.

TrumpRx.gov lives now — search, print, save. For 50 million uninsured and deductibled Americans, relief arrives. Scale remains question; impact, already real.

Business

Stifel raises Cullinan Oncology stock price target on autoimmune progress

Published

4 minutes ago

10 March 2026

NewsAdmin

Stifel raises Cullinan Oncology stock price target on autoimmune progress

Business

Crexendo: AI, Acquisitions And A Growing Software

Published

10 minutes ago

10 March 2026

NewsAdmin

Crexendo: AI, Acquisitions And A Growing Software

Business

Saba Capital’s Boaz Weinstein warns private credit problems are multiplying

Published

19 minutes ago

10 March 2026

NewsAdmin

Saba Capital's Boaz Weinstein warns private credit problems are multiplying

Inside Alts: Saba Capital's Boaz Weinstein on private credit's liquidity problem

A version of this article appeared in CNBC’s Inside Alts newsletter, a guide to the fast-growing world of alternative investments, from private equity and private credit to hedge funds and venture capital. Sign up to receive future editions, straight to your inbox.

The problems in private credit are “multiplying by the quarter,” due in part to the “financial alchemy of promising liquidity that isn’t there,” Boaz Weinstein, founder of Saba Capital Management, told Inside Alts this week.

“What’s happening, big picture, right now is that, for a number of reasons, in the middle of a bull market, there are cracks, there are problems, there are frauds, there are companies that are going bad without being a fraud,” Weinstein said in an exclusive interview. “So for those reasons, investors are seeing their dividends being cut. They want their money back, and [on] Wall Street the No. 1 story right now is where the redemption is going to be for all these managers.”

Weinstein, of course, is a central figure in that story. His firm, Saba, alongside Cox Capital Management, just launched a tender offer to purchase 6.9% of shares in one of Blue Owl’s nontraded private credit funds at a 34.9% discount.

“We were hearing from investors in these funds that they wanted their money back,” he said. “They were trying to find someone to step into their shoes, so that happened in an organic way.”

That fund, known as Blue Owl Capital Corp. II, halted quarterly redemptions and sold $1.4 billion of direct lending investments to provide liquidity for its investors. It turned out to be among the first in a slew of nontraded, private credit funds that have been hit with redemption requests above the typical 5% quarterly cap.

Private wealth flows across products tracked by analysts at Jefferies were down 19% in the first quarter compared with Q4. Analysts said they expect redemption rates across retail credit products to increase.

Saba and Cox see an opportunity amid investors’ limited liquidity. They are launching similar tenders for stakes in several other funds at Blue Owl as well as Starwood Real Estate Income Trust. This has caused some to question whether Weinstein has been criticizing the private credit industry only to scare retail investors into selling their stakes to him at a discount.

While speaking with Inside Alts, Weinstein clarified that he doesn’t actually believe there will be a wave of private credit defaults or frauds, nor does he think people should redeem further. (“The redemptions have arrived,” he said.)

In fact, he’s actually bullish on several of the largest private credit managers. Weinstein said over the past few weeks, he bought shares in “the most amazing managers,” including Ares, Apollo and Blackstone. He said he is even long “a little bit” of Blue Owl equity.

“We’re long the stocks of these companies on the idea that, in case this is overdone, these are the guys that are going to be the winners at the end, when the smoke clears and their stocks may represent good value,” said Weinstein.

Get Inside Alts directly to your inbox

Weinstein said he thinks private credit is trading at pessimistic levels and public credit is trading at “incredibly optimistic levels.” He’s shorted public credit through credit default swaps and credit derivatives. Weinstein said that the gating of private credit funds means that investors will have to sell more liquid assets to raise cash, which would weigh on the market.

“I think that public credit is incredibly mispriced and part of my short-term thinking about it is informed by the issues that the private credit markets are having,” he said.

Weinstein said it will be a “number of weeks” before they know what happens with the Blue Owl bids, and how much they’ll end up buying. Weinstein said the tender offers weren’t “personal” against the manager, but rather, he said, “if we go bid for something, it’s a sign we think the manager is good.”

However, Weinstein noted a firm called Cliffwater as one in the private credit space that they’re “watching the most closely.” He said Cliffwater operates similarly to a fund-of-funds model, where they don’t own the loans directly, but rather, they’re invested in other managers. As a result, they have limited control over fulfilling their own redemption requests – something Weinstein describes as a “turducken” (a chicken stuffed inside a duck, stuffed inside a turkey).

According to a Securities and Exchange Commission filing, Cliffwater disclosed that as of the end of last year, 69% of its Corporate Lending Fund was comprised of direct investments in underlying credit and the remaining 31% was exposed to funds.

Weinstein predicted that when Cliffwater announces its redemption rate — expected as early as Tuesday — it could be between 10% and 20%.

“I don’t know their exact cash position, but we think it’s very likely that they’re going to have to start redeeming and they’re going to get cut back when they redeem these funds that they’ve invested in,” he said.

Cliffwater was also the subject of a recent viral investor letter by the hedge fund Rubric Capital, which said the alternatives manager could be “a canary in a coal mine” and “the first domino in the bank run we foresee,” according to The New York Times, which cited two people who read the private note.

When asked about what happens to private credit if there’s a real credit cycle, Weinstein said, “it will fall harder than it should.”

He added that “one of the best opportunities” in his career would be investing in private credit at a massive discount “when the economy slows.”

“Maybe that’s not for a year, maybe it’s about to happen. Maybe it’s going to happen years from now,” Weinstein said. “It’s about to get super interesting.”

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.

Business

Cantor Fitzgerald raises Neurocrine Bio price target on Ingrezza outlook

Published

24 minutes ago

10 March 2026

NewsAdmin

Cantor Fitzgerald raises Neurocrine Bio price target on Ingrezza outlook

Business

DA Davidson reiterates Repay stock Buy rating on strong Q4 results

Published

33 minutes ago

10 March 2026

NewsAdmin

DA Davidson reiterates Repay stock Buy rating on strong Q4 results

Business

ABM Q1 2026 slides: revenue beats offset by margin pressure

Published

39 minutes ago

10 March 2026

NewsAdmin

ABM Q1 2026 slides: revenue beats offset by margin pressure

Business

Tekmar encouraged by momentum and record order book despite drop in revenues

Published

47 minutes ago

10 March 2026

NewsAdmin

Tekmar encouraged by momentum and record order book despite drop in revenues

The County Durham offshore engineering group says it is seeing positive signs

Offshore technicians assembling Tekmar’s patented TEKLINK cable protection system during offshore installation on an offshore wind farm(Image: Unknown)

Offshore energy group Tekmar says it is encouraged by its latest results, despite seeing a drop in revenues and another year of losses.

The County Durham-based firm, which provides asset protection technology and offshore energy services, has released results for the year ending September 30 2025.

They show turnover falling slightly to £28.7m, while gross profit fell to £9.8m. After taking into account exceptional items, depreciation and other costs, Tekmar reported an overall loss for the year of £3.9m, though this was less than last year’s losses.

But Tekmar said that £43m of new orders since last July and currently had a record order book. It said its balance sheet had been strengthened, including by the sale of its former Innovation House building for £2.8m.

The company said its Project Aurora plan to scale the business through both organic growth and acquisitions, and to improve its financial strength, was progressing well.

CEO Richard Turner said: “FY25 has been a pivotal and highly productive year for Tekmar as we launched and started to execute on Project Aurora. The group delivered results in line with market expectations, alongside a material improvement in profitability in the second half.

Richard Turner, CEO Tekmar Group plc(Image: Tekmar Group plc)

“We are pleased to have been able to maintain our momentum post period end – in the first four months of FY26 we have delivered a record order book, with multi-year visibility and have unlocked further growth potential by significantly strengthening our balance sheet.

“We are encouraged by the strong start to the new financial year and healthy pipeline we see ahead of us and are focused on delivering sustained, profitable growth and enhanced value for shareholders.”

Business

Welsh energy consultancy firm collapses into administration with nearly 140 job losses

Published

54 minutes ago

10 March 2026

NewsAdmin

Welsh energy consultancy firm collapses into administration with nearly 140 job losses

Cardiff-based Amber Energy Solutions had been experiencing cashflow problems

Generic energy usage statement

Cardiff-based energy management consultancy Amber Energy Solutions has collapsed into administration resulting in nearly 140 staff being made redundant. The business provided energy consultancy and data services to multi-site property portfolios, landlords and infrastructure operators across the UK.

Amber Energy, which traded strongly in 2024, experienced cash flow challenges and a decline in revenues through 2025.

Matt Whitchurch and Jonathan Dunn of specialist business advisory firm FRP were appointed joint administrators.

Prior to appointment FRP said it undertook an accelerated marketing process to explore options for the business and its assets. While there was initial interest from a number of parties, only limited asset sales were ultimately achievable. A solvent sale was explored, but did not proceed after interested parties withdrew.

Immediately following their appointment, the joint administrators completed the sale of certain assets.

However, the sale did not provide for the transfer of the wider workforce and 138 of the company’s 143 employees have been made redundant. The joint administrators are supporting those affected with claims to the Redundancy Payments Service.

Mr Whitchurch, partner at FRP, said: “Amber Energy Solutions had established a well-regarded offering in its sector but was unable to overcome sustained cash flow pressures.

“We explored options to secure a wider going concern solution, however this was not achievable in the circumstances. While sales of certain assets have been completed, the majority of roles have unfortunately been made redundant.

“Our focus now is on supporting employees through the claims process and working to maximise recoveries for creditors.”

Its last published financial accounts with Companies House, for its l 2024 financial year, showed the business experienced a strong rise in revenues on the previous year from £9.51m to £11.43m. It also posted a rise in profit to £1.51m.

The business was set up in 2009 by Nicholas Proctor. It had featured in the Wales Fast Growth 50 initiative, an annual league table of the fastest-growing indigenous firms in Wales based on revenue growth.

Business

NSE tells brokers to disclose and remit excess STT retained for FY24 and earlier years

Published

1 hour ago

10 March 2026

NewsAdmin

NSE tells brokers to disclose and remit excess STT retained for FY24 and earlier years

Leading exchange NSE has directed its members, including brokers and sub-brokers, to disclose and remit any excess Securities Transaction Tax (STT) collected but not deposited with the government for the financial year 2023-24 and earlier periods.

In a circular issued on March 10, the exchange said the move follows directions from the Income Tax Department, which flagged instances where excess STT collected by some market intermediaries had not been remitted to the government account.

STT is a tax levied on transactions executed on recognised stock exchanges and is collected by brokers at the time of trading before being deposited with the government.

According to the circular, the Joint Commissioner of Income Tax, Range 7(1), wrote to the exchange on March 5, advising it to draw attention to the issue and seek details from members who may have retained excess STT.

Following the instruction, NSE has asked all members to furnish details of such excess STT collected and retained with them for FY24 and preceding years. These details must be submitted directly to the exchange.

The exchange has also instructed brokers to remit any excess STT collected along with interest calculated at 1% for every month of delay. The funds must be paid to NSE immediately, after which the exchange will deposit the amount into the government account.
Members have been asked to comply with the directive within seven days from the publication of the circular.Also read | Everyone selling IT stocks after record crash, but this Rs 1.3 lakh crore mutual fund doing the exact opposite

The communication is a continuation of an earlier circular issued on March 19, 2025, which dealt with excess STT retained by members for FY23 and earlier years.

STT forms an important part of the tax framework governing equity and derivatives trading in India. The levy is applied across a range of market transactions including equity delivery trades, intra-day equity trades and derivatives contracts.

While brokers are responsible for collecting the tax from investors at the time of trade execution, they are required to deposit the amount with the government through the exchange system. Any delay or discrepancy in remittance can attract penalties or interest liabilities under tax rules.

NSE said members seeking clarification on the circular can contact its taxation department.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)